Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs
Novartis said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novartis
since
auto-detected in 16 stories
16 days ago
39 days ago
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done'
Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.
41 days ago
Novartis set to buy Avidity Biosciences for more than $10bn
found
a story from Financial Times ✅ › Financial Times
Deal would be biggest acquisition under chief executive Vas Narasimhan
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports ⊕
found
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
3 months ago
How Novartis got ahead on ‘incredible’ cancer breakthrough
Swiss pharma group has become a pioneer in radioligand therapy, a new type of targeted radiotherapy
Cholesterol-busting jab given twice a year could transform heart care, its maker says
It comes as new trial data suggests Leqvio, also known as inclisiran and made by Novartis, helped patients meet their cholesterol goals faster than other therapies.
NHS to lose out on new drugs due to skyrocketing costs, pharma firm warns
The claims from pharmaceutical giant Novartis comes amid a row over drug pricing deals.
4 months ago
Novartis weighs deal for biotech Avidity to boost drug pipeline
Pharma companies seek deals to replace revenue they will lose due to looming patent cliffs
Trump's pharmaceutical tariffs could affect some drugmakers more than others
found
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Sales of breast cancer drug Kisqali grew 100% in the U.S. in the three months to June.